铜-Aβ和细胞染色体c:在阿尔茨海默氏病中潜在的Janus
Chinmay Dey1, Puja Pal1, Rimi Ghosh1
1School of Chemical Sciences, Indian Association for the Cultivation of Science, 2A & 2B, Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India. icsgd@iacs.res.in.
Dalton transactions (Cambridge, England : 2003)
|July 23, 2025
概括
在线粒体中,细胞染色体c (Cyt c) 与铜结合的粉样蛋白-β (Aβ) 的相互作用具有双重效应. 细胞细胞可以减少反应性氧物种 (ROS) 的产生,但氧化Cu-Aβ也加速细胞细胞氧化,可能导致阿尔茨海默病的脑细胞死亡.
科学领域:
- 线粒体的生物化学
- 神经退行性疾病机制的神经退行性疾病机制
- 生物学中的金属离子相互作用
背景情况:
- 胺ββ (Aβ) 和细胞染色体c (Cyt c) 在线粒体中共存.
- 阿尔茨海默病 (AD) 病理包括氧化应激和线粒体功能障碍.
- 铜结合的Aβ (Cu-Aβ) 和Cyt c之间的分子级相互作用尚未得到充分理解.
研究的目的:
- 为了阐明Cu-Aβ和Cytc之间的分子相互作用.
- 研究这些相互作用在活性氧物种 (ROS) 生成中的作用.
- 为了探索对阿尔茨海默氏症病原发生的影响.
主要方法:
- 用光谱分析来研究Cu-Aβ和Cytc之间的电子转移.
- 研究不同条件下的ROS生产,涉及Cu-Aβ和Cytc.
- 评估由氧化Cu-Aβ催化的Cytc过氧化酶类活性.
主要成果:
- 减少的Cu-Aβ将电子转移到氧化Cytc,减轻通过减少的Cu-Aβ产生ROS.
- Cyt c 证明了对来自Cu-Aβ的ROS生成的保护作用.
- 氧化Cu-Aβ显著加快了由过氧化 (H2O2) 减少Cytc的氧化,显示出Cytc过氧化酶的活性.
结论:
- 通过减少由Cu-Aβ产生的ROS,Cytc可以起到保护作用.
- Cu-Aβ表现出内在的Cyt c过氧化酶活性,导致氧化Cyt c.
- 这种Cu-Aβ催化Cytc氧化可能会导致脑细胞死亡,这是AD的标志.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


